US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Articles published by Annovis Bio Inc.

< Previous 1 2 Next >
News headline image
Annovis Announces Partnership with Weave Bio, AI Regulatory Platform, in Preparation of NDA for Buntanetap in Alzheimer’s Disease
From Annovis Bio Inc.
Via GlobeNewswire
Tickers ANVS
News headline image
Annovis to Host Corporate Update Webinar on September 2, 2026
From Annovis Bio Inc.
Via GlobeNewswire
Tickers ANVS
News headline image
Annovis Provides Corporate Updates and Second Quarter 2026 Financial Results
From Annovis Bio Inc.
Via GlobeNewswire
Tickers ANVS
News headline image
Annovis Reaches Full Enrollment in Pivotal Phase 3 Trial of Buntanetap for Early Alzheimer’s Disease
From Annovis Bio Inc.
Via GlobeNewswire
Tickers ANVS
News headline image
Annovis Appoints Cheng Fang, Ph.D., as Chief Scientific Officer
From Annovis Bio Inc.
Via GlobeNewswire
Tickers ANVS
News headline image
Annovis Bio Regains NYSE Listing Compliance
From Annovis Bio Inc.
Via GlobeNewswire
Tickers ANVS
News headline image
Annovis Announces Pricing of $15.0 Million Public Offering of Common Stock and Accompanying Warrants
From Annovis Bio Inc.
Via GlobeNewswire
Tickers ANVS
News headline image
Annovis Announces Launch of Proposed Public Offering of Common Stock and Accompanying Warrants
From Annovis Bio Inc.
Via GlobeNewswire
Tickers ANVS
News headline image
Annovis Provides Corporate Updates and Reports First Quarter 2026 Financial Results
From Annovis Bio Inc.
Via GlobeNewswire
Tickers ANVS
News headline image
Annovis CEO to Present on Multi-Protein Model of Alzheimer's Disease at Fierce Biotech Week 2026
From Annovis Bio Inc.
Via GlobeNewswire
Tickers ANVS
News headline image
Annovis Publishes Phase 2/3 Alzheimer's Trial Results in Nature Portfolio
From Annovis Bio Inc.
Via GlobeNewswire
Tickers ANVS
News headline image
Annovis Closes $10 Million Offering, Extending Cash Runway Through Phase 3 Alzheimer's Disease 6-Month NDA Submission
From Annovis Bio Inc.
Via GlobeNewswire
Tickers ANVS
News headline image
Annovis Announces $10 Million Underwritten Offering of Common Stock and Accompanying Warrants
From Annovis Bio Inc.
Via GlobeNewswire
Tickers ANVS
News headline image
Annovis Secures U.S. Patent for Buntanetap in the Prevention and Treatment of Neurological Injuries Caused by Brain Infections
From Annovis Bio Inc.
Via GlobeNewswire
Tickers ANVS
News headline image
Annovis Publishes Historical Review of Buntanetap in The Scientist
From Annovis Bio Inc.
Via GlobeNewswire
Tickers ANVS
News headline image
Annovis Partners with NeuroRPM to Deploy AI-Powered Digital Biomarker Technology in Parkinson's Disease Study
From Annovis Bio Inc.
Via GlobeNewswire
Tickers ANVS
News headline image
Annovis Provides Corporate Updates and Reports Fiscal Year 2025 Financial Results
From Annovis Bio Inc.
Via GlobeNewswire
Tickers ANVS
News headline image
Annovis Announces Two Presentations at the AD/PD™ 2026 International Conference
From Annovis Bio Inc.
Via GlobeNewswire
Tickers ANVS
News headline image
Annovis Secures DSMB Approval to Advance Pivotal Phase 3 Trial of Buntanetap in Alzheimer’s Disease
From Annovis Bio Inc.
Via GlobeNewswire
Tickers ANVS
News headline image
Annovis Announces Open-Label Extension Study for Parkinson's Disease Patients
From Annovis Bio Inc.
Via GlobeNewswire
Tickers ANVS
News headline image
Annovis to Host Corporate Update Webinar on January 28, 2026
From Annovis Bio Inc.
Via GlobeNewswire
Tickers ANVS
News headline image
Annovis To Present at the 2025 Annual Meeting of the Parkinson Study Group
From Annovis Bio Inc.
Via GlobeNewswire
Tickers ANVS
News headline image
Annovis Announces Two Presentations at the CTAD 2025 Conference
From Annovis Bio Inc.
Via GlobeNewswire
Tickers ANVS
News headline image
Annovis Announces FDA Meeting to Discuss Parkinson's Disease Dementia Program; Reaffirms FDA Alignment on Pivotal Phase 3 Alzheimer's Disease Study
From Annovis Bio Inc.
Via GlobeNewswire
Tickers ANVS
News headline image
Annovis Reports New Biomarker Data Linking Amyloid Co-Pathology to Accelerated Cognitive Decline in Parkinson's Patients
From Annovis Bio Inc.
Via GlobeNewswire
Tickers ANVS
News headline image
Annovis Provides Corporate Updates and Reports Third Quarter 2025 Financial Results
From Annovis Bio Inc.
Via GlobeNewswire
Tickers ANVS
News headline image
Annovis Achieves Significant Milestones and Sustains Strong Progress in Phase 3 Alzheimer’s Program
From Annovis Bio Inc.
Via GlobeNewswire
Tickers ANVS
News headline image
Annovis Announces $3.4 Million Registered Direct Offering of Common Stock Priced At-the-Market under the NYSE Rules
From Annovis Bio Inc.
Via GlobeNewswire
Tickers ANVS
News headline image
Annovis Announces Closing of $6 Million Registered Direct Offering of Common Stock
From Annovis Bio Inc.
Via GlobeNewswire
Tickers ANVS
News headline image
Annovis Announces $6 Million Registered Direct Offering of Common Stock
From Annovis Bio Inc.
Via GlobeNewswire
Tickers ANVS
< Previous 1 2 Next >